Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952611 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1954034 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1955664 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1952774 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1952285 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1955320 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1954257 | 0.98 | NAAA (0.48) | NAAAIDO1HCAR3CNR1CNR2 | |
| SCHEMBL1955524 | 0.95 | IDO1 (0.46) | NAAAIDO1HCAR3CYP19A1CHEK1 | |
| SCHEMBL1953380 | 0.87 | IDO1 (0.58) | IDO1HCAR3CYP19A1CHEK1PIM1 | |
| SCHEMBL1954771 | 0.84 | NAAA (0.43) | NAAAIDO1HCAR3CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244957-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | Merck Patent KGaA (DE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126635-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| CN-118044354-A | Method for forming organic element of electronic device | 默克专利有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4340969-A1 | METHOD FOR THE CONTINUOUS PURIFICATION OF AT LEAST ONE FUNCTIONAL MATERIAL AND DEVICE FOR THE CONTINUOUS PURIFICATION OF AT LEAST ONE FUNCTIONAL MATERIAL | Merck Patent GmbH (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-117730638-A | Printing method by combining inks | 默克专利有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4326826-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | Merck Patent GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| CN-117355364-A | Method for continuously purifying at least one functional material and device for continuously purifying at least one functional material | 默克专利有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023237458-A1 | METHOD OF PRINTING A FUNCTIONAL LAYER OF AN ELECTRONIC DEVICE BY COMBINING INKS | MERCK PATENT GMBH (DE) | 2023-12-14 | — | — | WO | disclosed |
| CN-117178031-A | Preparation of organic functional material | 默克专利有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3475372-B1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2023-11-22 | — | — | EP | disclosed |
| WO-2012013270-A1 | NANOCRYSTALS IN DEVICES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011147522-A1 | COMPOSITIONS COMPRISING QUANTUM DOTS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011110275-A2 | RADIATIVE FIBERS | MERCK PATENT GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110277-A1 | FIBERS IN THERAPY AND COSMETICS | MERCK PATENT GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011076323-A1 | FORMULATIONS COMPRISING PHASE-SEPARATED FUNCTIONAL MATERIALS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076314-A1 | ELECTROLUMINESCENT FORMULATIONS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076326-A1 | ELECTROLUMINESCENT FUNCTIONAL SURFACTANTS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011069590-A1 | THERAPEUTIC AND COSMETIC ELECTROLUMINESCENT COMPOSITIONS | MERCK PATENT GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2011015265-A2 | ELECTRONIC DEVICES COMPRISING MULTI CYCLIC HYDROCARBONS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | NAAA 57/4885IDO1 2297/4885HCAR3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.